Please ensure Javascript is enabled for purposes of website accessibility

Got $4,000? Buy These 2 Cannabis-Focused Biotech Stocks

By Alex Carchidi – Aug 31, 2021 at 6:37AM

Key Points

  • There are many niches within the biotech industry, and more than one of them relates to cannabis.
  • Both of these companies are likely to increase in value as their overlapping industries progress.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Neither of them needs to sell marijuana to consumers to succeed.

As different as they may seem, there's some overlap between the cannabis industry and biotech that's worth understanding as an investor. Cultivators can use biotechnology to manipulate the genes of marijuana plants to increase their yield, and biotechs can use the bioactive chemicals contained in cannabis as jumping-off points for drug development efforts. 

Both of the companies I'll analyze today conduct their business within these overlapping regions. And, if their efforts continue to pan out as planned, they'll be valuable stocks to own, especially as the biotech sector becomes more sophisticated and as the cannabis industry scales to match global demand. 

A smiling scientist holds up a petri dish to the light while working at a cluttered laboratory bench.

Image source: Getty Images.

1. Jazz Pharmaceuticals

Jazz Pharmaceuticals (JAZZ 0.81%) is pushing forward with cannabis-derived medicines for rare diseases, and it's gaining momentum rapidly. On Aug. 10, its epilepsy drug, Epidiolex, received an expanded indication in the U.K. for seizures stemming from a rare disease called tuberous sclerosis complex, which followed a similar approval in the U.S. The new indication is the fourth for Epidiolex, which is a prescription-only formulation of the chemical cannabidiol (CBD), a non-psychoactive component of cannabis.

Epidiolex revenue is ramping up sharply; sales rose by 32% year over year in Q2 to reach $155.9 million. The company is already angling for a fifth indication, with a phase 3 study examining the drug's merit for myoclonic-atonic seizures (a rare form of epilepsy) set for the first half of 2022.

But there's more to Jazz's cannabinoid pipeline than cannabidiol. Aside from its undisclosed programs, it has several other clinical-stage projects investigating the cannabinoid mixture called nabiximols for conditions like multiple sclerosis (MS) spasticity, schizophrenia, and post-traumatic stress disorder (PTSD). One common trend among these disorders is that they're hard to treat, and the currently existing medicines aren't that effective.

So, if Jazz's candidates can succeed where other therapies have failed, it'll be able to claim a market-leading position relatively easily, and that's exciting. And even if Jazz's programs aren't knockouts, they could still capture some market share by being used as adjunct treatments on top of the existing solutions. 

Of course, Jazz is a relative newcomer to the cannabis therapeutics space. Before its acquisition of GW Pharmaceuticals, where most of its cannabinoid pipeline originated, the company developed a handful of drugs for applications in oncology and neurology. In fact, its oncology portfolio alone is slated to make Jazz as much as $835 million in revenue during 2021, destroying 2020's record of $554 million. So, there's a lot more to this stock than its lucrative cannabinoid medicines, and that's one more reason why it's worth a purchase.

2. 22nd Century Group

Helping other businesses make more money is an effective and time-tested strategy, and that's exactly what 22nd Century Group (XXII 3.51%) does with its cannabis genetics platform. By modifying the genes of marijuana plants, the company increases their yield of valuable cannabinoid chemicals.

That's a hotly desired capability among cannabis growers, as it helps them to get more out of their limited cultivation space without increasing the required labor or cultivation footprint. And if the growers want to increase their plants' production of specific cannabinoids and suppress others, 22nd Century can do that too, thereby opening the door for a smattering of new product differentiation opportunities. 

There are two key trends that make 22nd Century's cannabis genetics platform insanely valuable. 

First, marijuana pure-play companies tend to struggle with profitability. This is caused in part by fluctuations in the fair-market value of marijuana and the associated cannabinoid chemicals, which require processing to extract. Increasing cannabinoid yields could be a major part of the solution to that problem, as less plant matter would be needed to generate the same quantity of cannabinoids. 

Second, global demand for marijuana is increasing alongside progress with legalization. Serving that demand at scale is a challenge that competitors are going to need to address by increasing their output. But overbuilding of output capacity relative to demand is another one of the industry's ongoing issues. Companies won't need to spin up as much new cultivation space to keep up with demand if they can count on higher yields.

In sum, 22nd Century's services will be in demand from large and small marijuana cultivators alike. If everything goes according to plan, the company will also start to register an increasing amount of revenue from licensing its genetics technologies throughout 2021 and beyond, putting it on the path to profitability. Furthermore, it could experience rising demand for the relatively small amounts of cannabis biomass and cannabinoid distillates that it produces in-house.  While it's true that cannabis companies don't need its help to succeed, they can score a major edge if they do, and that's what makes this stock worth buying.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Jazz Pharmaceuticals Stock Quote
Jazz Pharmaceuticals
JAZZ
$156.91 (0.81%) $1.26
22nd Century Group Stock Quote
22nd Century Group
XXII
$1.18 (3.51%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.